Competitive Technologies, Inc. offers a non-invasive pain therapy without the harmful side effects of narcotic painkillers. Cleared for use in the US by the Food and Drug Administration (FDA), the device offers a non-invasive method without harmful side effects for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. CTT's pain therapy also has Medical Device CE certification from the European Union.
In the past several months, the FDA has addressed some serious concerns about the safety of a number of harmful narcotic medications used to relieve pain, including morphine, Demerol, Vicodin, Percocet and Acetaminophen. With limited options for patients suffering from debilitating pain, especially those at the end of life, the FDA has been reluctant to remove these powerful harmful narcotics from the market. CTT’s pain therapy medical device offers an effective, proven option for patients and medical professionals providing palliative care. This non-invasive pain therapy without harmful side effects is based on a biophysical rather than a biochemical approach, using a multiprocessor to simultaneously treat multiple pain areas by applying surface electrodes to the skin.
CTT’s pain therapy medical device is currently being used by clinical investigators at the Virginia Commonwealth University Massey Cancer Center for independent clinical research to examine the device’s ability to decrease pain associated with chemotherapy-induced peripheral neuropathy (CIPN).
This device brings CTT to the forefront in addressing the needs of palliative care patients and the improvement of palliative healthcare in the US and globally, said John B. Nano, CTT’s Chairman, President and CEO. We have all learned from recent press coverage about celebrities suffering from injury or cancer induced pain, including Michael Jackson, Keith Richards, Farah Fawcett, and countless others. At the same time there are thousands of other people without the celebrity attention suffering from pain. Prior to our device, their only source of pain relief has been narcotics that are highly toxic, harmful and addictive. Our European studies on over 3,000 patients have shown that this device is highly effective for treating oncologic and neuropathic pain. This technology is a prime example of our strategy to connect clinical science to patient care.
Following FDA authorization in February 2009, our initial focus in the US has been to major US cancer centers, and to select medical equipment distributors for sales to hospitals, pain clinics, hospice centers and pain management specialists, said Aris D. Despo, CTT’s Executive VP, Business Development. The FDA clearance and our international distributors are significant steps in CTT’s global commercialization of this breakthrough medical device, which offers relief to patients suffering extreme pain. Our device provides a valuable tool to the clinician in offering an effective treatment program that can positively impact patients’ quality of life, especially patients who have not otherwise responded to standard therapeutic protocols, including morphine.